Vol. 2, Issue 16   |   October 27, 2026

GERD and early surgical risk, cancer prevention, and skeletal and psychological outcomes after surgery lead this issue. Retatrutide sleep-apnea trials and the economics of obesity coverage extend the discussion beyond weight loss.

Highlighted Article of Interest

Ronald R. Grunstein, Virend K. Somers, Ali Azarbarzin, et al. | New England Journal of Medicine, Oct. 21, 2026 | 10.1056/NEJMoa2611477

Eli Lilly funded two randomized OSA trials enrolling adults with overweight or obesity: 243 without diabetes and 448 with type 2 diabetes. Weekly subcutaneous retatrutide began at 2 mg and escalated every four weeks to 4, 9 or 12 mg. At week 80, hybrid-treatment estimates of apnea–hypopnea index (AHI) change at 9/12 mg were −34.3/−31.7 events/hour versus −9.9 with placebo without diabetes. With diabetes, changes were −24.7/−25.4 versus −10.3 events/hour.

At 9 mg without diabetes, the AHI difference versus placebo was −24.4 events/hour (95% CI −34.1 to −14.7); intention-to-treat results were similar. Adverse events occurred in 88–93% versus 76% without diabetes and 73–84% versus 71% with diabetes, for retatrutide versus placebo. Most were gastrointestinal; serious events occurred in 8% versus 10% in each trial. These sleep-study gains do not establish long-term cardiovascular benefit, which the trials did not assess.

KEY FINDING

At 80 weeks, retatrutide 9 mg reduced AHI by 34.3 events/hour versus 9.9 with placebo in adults without diabetes. Both primary doses also improved AHI in the diabetes trial.

A — Metabolic Surgery Research

Héctor J García-Navas, Emily Jordan, Florina Corpodean, et al. | Surgery for Obesity and Related Diseases, Sep. 21, 2026 | 10.1016/j.soard.2026.09.010

Disclosure: MBS Digest editorial board member Philip R Schauer is a coauthor of this study.

Preoperative GERD was associated with modestly higher postoperative risk in an adjusted MBSAQIP analysis of 1,282,883 patients treated during 2015–2022. GERD was recorded in 30.5% of patients. Compared with patients without GERD, adjusted odds ratios were 1.27 for infections, 1.20 for serious complications and 1.28 for 30-day readmission. Sleeve gastrectomy remained more common than gastric bypass regardless of GERD status.

The association concerns early morbidity, a different endpoint from the long-term reflux outcomes that often dominate procedure comparisons. Infection, serious complications and readmission all showed a similar direction of association after adjustment. GERD therefore appears to carry perioperative risk information across several outcomes. As an observational registry analysis, the study cannot separate a causal reflux effect from differences in patients who have GERD.

KEY FINDING

Adjusted odds of infection were 1.27 times those in patients without GERD. The association extends the relevance of reflux beyond postoperative symptom control.

Amanda Belluzzi, Maurizio De Luca, Antonio Vitiello, et al. | Obesity Surgery, Oct. 6, 2026 | 10.1007/s11695-026-08966-x

An IFSO position statement links metabolic bariatric surgery with lower incidence of several cancers versus nonsurgical care. Its review included 26 studies, with no randomized trial reporting cancer incidence. Pooled incidence rate ratios were 0.85 for breast cancer (95% CI 0.80–0.91), 0.38 for endometrial cancer (0.23–0.61) and 0.72 for colorectal cancer (0.59–0.88). No single pooled estimate drew on more than seven studies.

Cancer risk reduction is a plausible additional benefit for patients already eligible for surgery on metabolic grounds. IFSO's conditional position does not support surgery solely for cancer prevention. Residual selection bias and heterogeneity leave the certainty low to very low across outcomes. For clinical interpretation, the distinction matters: consistent relative associations can inform expectations without defining an individual's absolute benefit or proving that surgery itself caused the reduction.

KEY FINDING

Across 26 studies, surgery was associated with lower incidence of several obesity-related cancers. IFSO treats this as an additional potential benefit of surgery for standard metabolic indications.

Walid El Ansari, Kareem El-Ansari, Mohamed Hany | Current Obesity Reports, Oct. 24, 2026 | 10.1007/s13679-026-00768-7

A scoping review of 251 studies describes psychological recovery after metabolic bariatric surgery as uneven over time. The authors grouped benefits into four domains and less desirable experiences into three themes; 37 studies contributed to both sides. Depression and anxiety improvements were greatest in the first year, then smaller or partly reversed. Benefits and burdens could coexist in the same patient, while severe adverse outcomes included suicide, self-harm and alcohol-use disorder.

A favorable average mental-health score can conceal patients whose symptoms persist or worsen. That makes psychological recovery a distinct outcome rather than a consequence that can be assumed from weight loss. The heterogeneous scoping evidence does not provide a pooled risk estimate or establish that surgery caused the adverse trajectories. Its clinical contribution is a fuller account of postoperative experience, including how changing relationships, body image and support needs can complicate early gains.

KEY FINDING

Thirty-seven studies described both psychological benefits and less desirable experiences after surgery. Early average improvement can coexist with a difficult later course for some patients.

Kinga Kędzierska, Maria Humięcka, Ada Sawicka, et al. | Obesity Surgery, Sep. 28, 2026 | 10.1007/s11695-026-08957-y

A prospective sleeve gastrectomy cohort found lower femoral-neck bone density after a median nine years. The 72 participants included 62 women and 10 men, with a mean age of 43.6 years. Femoral-neck BMD fell by 0.10 g/cm² (p<0.001), whereas the lumbar-spine change of −0.03 g/cm² was not statistically significant (p=0.180). Body weight decreased from 112.8 to 91.5 kg over follow-up, so sustained weight reduction and skeletal loss were both present.

The different hip and spine findings argue against treating bone density as a single uniform postoperative outcome. Changes in BMD did not correlate significantly with changes in weight, BMI, fat mass or lean mass. The small, predominantly female cohort limits generalizability to the wider sleeve population. The persistence of femoral-neck loss nearly a decade after surgery places skeletal change alongside durable weight reduction among the long-term outcomes of this cohort.

KEY FINDING

Femoral-neck BMD fell by 0.10 g/cm² over a median nine years after sleeve gastrectomy. This densitometric result does not quantify fracture risk.

B — Science of Obesity Metabolism

Dimitris C. Kounatidis, Natalia G. Vallianou, Marina Kouveletsou, et al. | Current Obesity Reports, Oct. 21, 2026 | 10.1007/s13679-026-00770-z

Gastrointestinal intolerance and a modest increase in gallbladder and biliary disease risk have the most consistent support in this narrative review of GLP-1 receptor agonist safety. Small heart-rate increases also recur across the evidence. Pancreatitis remains a concern, although findings conflict. The authors distinguish these effects from less settled associations involving vision, psychiatric symptoms, aspiration and malignancy.

The authors place gastrointestinal and biliary effects within a favorable overall benefit-risk assessment for GLP-1 therapy. Their account separates recurring tolerability problems from rarer reported events involving vision, psychiatric symptoms and malignancy. Reporting bias and confounding weaken causal interpretation of those emerging associations. This distinction explains why a broad list of reported events is not equivalent to a list of established drug complications.

KEY FINDING

Gastrointestinal and biliary effects have more consistent support than many emerging GLP-1 safety signals. The review distinguishes established adverse effects from associations still under investigation.

Clarissa Dakin, Jordan D. Beaumont, Beverley O'Hara | Obesity Reviews, Oct. 19, 2026 | 10.1111/obr.70245

A systematic review of 25 articles involving 4,060 adults compared energy intake with GLP-1-based therapies against control conditions. Participants were 64% female, with a mean age of 44 years and mean BMI of 36.7 kg/m². The pooled standardized mean difference was −0.775 (95% CI, −1.21 to −0.34; P=0.002). The negative standardized effect favored lower intake with treatment, alongside greater appetite suppression.

The energy-intake effect varied substantially across studies, with heterogeneity of 82.7% and a prediction interval that included no effect. Only four studies had low risk of bias. This variability limits the usefulness of the pooled average for predicting a particular treatment setting. The synthesis connects GLP-1 therapy to reduced intake, while the standardized effect describes differences across study measures rather than a single daily calorie reduction.

KEY FINDING

The pooled standardized difference in energy intake was −0.775 in favor of GLP-1-based treatment. It supports an average intake effect, rather than a fixed calorie reduction.

Yudan Wang, Xinhao Fan, Jingyuan Gao, et al. | Current Obesity Reports, Sep. 16, 2026 | 10.1007/s13679-026-00761-0

This review connects obesity-associated osteoarthritis to mechanical loading, adipose inflammation and persistent cellular changes after weight loss. It summarizes a 407-person trial of weekly semaglutide 2.4 mg over 68 weeks. WOMAC pain scores fell 41.7 points with semaglutide versus 27.5 with placebo. WOMAC physical-function scores fell 41.5 versus 26.7 points, placing symptomatic benefit alongside the review’s proposed mechanisms of joint injury.

The proposed explanation for residual joint disease is that obesity leaves inflammatory and epigenetic changes that outlast fat loss. The authors therefore propose pairing weight reduction with treatments directed at those persistent changes, including potential roles for semaglutide and metformin. Much of that rationale comes from experimental models, and the combined strategy lacks clinical validation. For bariatric practice, persistent pain after weight loss need not mean that weight reduction had no value.

CONTEXT

WOMAC pain improved by 41.7 versus 27.5 points in the semaglutide trial summarized by the review. Treating persistent obesity-related cellular changes remains an experimental extension of those clinical gains.

C — Coming Thursday on The Staple Line

The Staple Line | Thursday, October 29, 2026, 6:00 AM ET | mbs-digest.com/podcast

Dr. Dan’s disclosures: proctor and instructor for Intuitive Surgical; shareholder and key opinion leader for Fractyl Health; founder and director of National Surgery Review. He took part in his own capacity, not on behalf of Summa Health or any other institution, entity or society.

The Staple Line’s first guest interview features Dr. Adrian Dan of Summa Health, Professor of Surgery at the Northeast Ohio Medical University (NEOMED) and a member of the ASMBS Board of Directors. He and MBS Digest Production Editor John D. Scott discuss where metabolic and bariatric surgery stands today, from a childhood in Romania, Algeria and Germany to the question of who will lead the next model of metabolic care.

LISTEN

The episode is available everywhere podcasts are found on Thursday, October 29, at 6:00 AM ET, including Apple Podcasts, Spotify and Amazon Music.

D — Metabolic Marketplace

Timothy M. Dall, Fang Chen, Tanvi Sapra, et al. | Diabetes, Obesity, and Cardiometabolic CARE, June 7, 2026 | 10.2337/doci25-0006

A microsimulation examined expanded obesity treatment in a population of 47.3 million commercially insured adults without baseline diabetes or cardiovascular disease. Over 5 years, it projected $9.7 billion in medical savings and $25.8 billion in workplace benefits. Medical, disability and productivity gains recovered 81% of direct treatment costs. The comparison was with current treatment patterns, rather than universal treatment uptake.

Adding monetized quality-of-life and mortality benefits produced a reported $59.1 billion net social value and $2.35 return per dollar invested. That return is societal value, not a cash surplus for health plans. Adverse-effect costs and quality-of-life losses were incompletely modeled, limiting the estimates. Several authors work for GlobalData, which consults for obesity-treatment manufacturers; other authors are American Diabetes Association employees.

KEY FINDING

Medical, disability and productivity gains recovered 81% of direct treatment costs in the model. The larger societal return includes a monetary valuation of better health.

AstraZeneca | AstraZeneca official press release, Oct. 15, 2026 | Source ↗

AstraZeneca's company release describes an AI drug-discovery agreement with insitro for MASH and cardiomyopathies. The deal includes $40 million upfront and up to approximately $1.46 billion in contingent development and commercial milestones. Potential single-digit royalties would depend on global sales. AstraZeneca receives exclusive worldwide rights to advance selected programs; the milestone ceiling is not committed spending.

Insitro will combine human and cellular data to identify disease drivers and advance nominated targets toward development candidates. AstraZeneca will handle subsequent clinical development and regulatory work. The release reports no patient outcomes, so it cannot establish efficacy, safety or faster development. For metabolic clinicians, the MASH focus is relevant to obesity-related liver disease, but this remains discovery work rather than an available treatment option.

CONTEXT

The agreement includes $40 million upfront, with approximately $1.46 billion in potential milestones. Those terms fund discovery and development ambitions rather than establish clinical benefit.

Intuitive Surgical, Inc. | Intuitive official investor release, Oct. 20, 2026 | Source ↗

Intuitive's company earnings release reports approximately 14% growth in worldwide da Vinci procedures in the third quarter of 2026. It placed 546 da Vinci systems, versus 427 a year earlier, including 315 da Vinci 5 systems. Revenue was $3.05 billion versus $2.51 billion a year earlier. The procedure figures span specialties rather than isolating bariatric surgery, so they cannot establish growth in metabolic surgery or better patient outcomes.

The company recorded a $450 million pretax charge for an antitrust settlement agreed in October without admission of liability or wrongdoing. Preliminary and final court approval remain pending. Among the quarter's placements, 291 systems used operating leases, including 160 with usage-based terms. Those leasing arrangements link part of the platform’s commercial model to ongoing procedure volume rather than equipment purchases alone.

CONTEXT

Da Vinci system placements reached 546 versus 427 a year earlier. Of the new placements, 291 used operating leases, including 160 with usage-based terms.

Coming Thursday — Editorial

MBS Digest editorial | Thursday, October 29, 2026

Disclosure: Dr. Schauer is a coauthor of the ARMMS-T2D report discussed in the editorial (Diabetes Care, 2026; doi:10.2337/dc26-1070).

On Thursday, MBS Digest will publish an editorial by editorial board member Philip R. Schauer, MD, on the ARMMS-T2D study. The study followed 262 adults with type 2 diabetes and obesity for up to 14 years after random assignment to metabolic-bariatric surgery or medical-lifestyle therapy. The editorial considers what the study’s predictors of diabetes remission and relapse mean for when surgery is considered. The editorial was approved for publication by a majority of the board’s voting editors.

Closing the gaps in knowledge...

Production Editor John D. Scott MD FACS | [email protected]

This issue's ballot: 9 of 10 board seats voted.
MBS Digest | October 27, 2026 | Vol. 2, Issue 16
For educational purposes only.